Images List Premium Download Classic

Liver Disease

Liver Disease-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Circulating microrna as a marker for hepatocellular carcinoma
Quest Diagnostics Investments Incorporated
June 14, 2018 - N°20180163274

Provided herein are methods for the diagnosis, or management of liver diseases, e.g., hepatocellular carcinoma, using profiles of the mirnas determined from cellular or acellular body fluids.. .
Ibat inhibitors for the treatment of liver diseases
Albireo Ab
June 14, 2018 - N°20180162904

The present invention regards specific ibat inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these ibat inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions..
Pharmaceutical composition for preventing and treating obesity or liver diseases, containg tlr7 agonist
Knotus Life Science Inc.
June 14, 2018 - N°20180161318

The present invention is based on the fact that imiquimod, which is a substance that enhances toll-like receptor 7 (tlr7) related to the innate immunity of a living body, is effective in the prevention and treatment of obesity or liver disease, and the present invention relates to a pharmaceutical composition for the prevention and treatment of obesity or liver disease, wherein ...
Liver Disease Patent Pack
Download 100+ patent application PDFs
Liver Disease Patent Applications
Download 100+ Liver Disease-related PDFs
For professional research & prior art discovery
inventor
  • 100+ full patent PDF documents of Liver Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Nanoveson(tm): treatment, biomarkers and diagnostic tests for liver diseases and comorbid disease
Nanoveson Llc
June 07, 2018 - N°20180156829

A method of treatment of liver diseases and comorbid diseases is disclosed wherein an oral dose of lipids in an amount effective to trigger the release of cholecystokinin (cck) into the duodenum to generate a major release of bile phospholipids from remodeled stores of triglycerides (tag) in the liver, is administered to a patient in need thereof, thereby causing the ...
Non-alcoholic fatty liver disease biomarkers
The Regents Of The University Of California
June 07, 2018 - N°20180155787

Methods, compositions, kits, and systems for characterizing the non-alcoholic fatty liver disease (nafld) state of a subject are provided. In some embodiments the methods, compositions, kits, and systems comprise at least one mirna selected from the differentially expressed mirnas listed in at least one of tables 1-4, 10-14, and 28-29.
Use of trimethazine in preparation of drugs for preventing and treating liver diseases
June 07, 2018 - N°20180153886

Disclosed is a use of trimethazine in the preparation of drugs for preventing and treating liver diseases. Trimethazine is capable of inhibiting activation of resting t-cells to activated lymphocytes, reducing release of cytokines, and reducing hepatocyte injury caused by immune system; inhibiting fatty acid metabolism in hepatocytes, and optimizing the energy process in hepatocytes; and maintaining normal function of mitochondrial ...
Liver Disease Patent Pack
Download 100+ patent application PDFs
Liver Disease Patent Applications
Download 100+ Liver Disease-related PDFs
For professional research & prior art discovery
inventor
  • 100+ full patent PDF documents of Liver Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Cholic acid derivative, and preparation method and medical use thereof
Shanghai Hansoh Biomedical Co., Ltd.
May 31, 2018 - N°20180148470

The present invention relates to a cholic acid derivative, and a preparation method and a medical use thereof. In particular, the present invention relates to a cholic acid derivative of formula (i), a stereoisomer, or a pharmaceutically acceptable salt thereof.
Hepatocytes and hepatic non-parenchymal cells, and methods for preparation thereof
The University Of Tokyo
May 31, 2018 - N°20180147242

The present invention pertains to hepatocytes, liver progenitor cells, cholangiocytes, liver sinusoidal endothelial progenitor cells, liver sinusoidal endothelial cells, hepatic stellate progenitor cells, hepatic stellate cells, and liver cellular tissue models, as well as to methods for preparing these cells. The present invention also pertains to a cell fraction comprising liver progenitor cells, liver sinusoidal endothelial progenitor cells, or hepatic ...
Composition for preventing or treating liver disease comprising pogostemonis herba extract
Research & Business Foundation Sungkyunkwan University
May 24, 2018 - N°20180140651

The present invention relates to a composition having a pogostemonis herba extract which can be effectively used for preventing or treating liver disease. It has been specifically confirmed that the pogostemonis herba extract of the present invention can be used to effectively reduce alt and il-6 levels in blood, tlr 4 protein expression level within a liver.
Metabolically programmed metal chelators and uses thereof
University Of Florida Research Foundation, Incorporated
May 24, 2018 - N°20180140581

The present invention provides compounds of formula (i), which are “metabolically programmed” metal chelators, e.g., lipophilic, absorbable (e.g., orally absorbable), and effective metal chelators that are converted in vivo to their hydrophilic, nontoxic metabolites. The present invention also provides compounds of formula (ii), which are also “metabolically programmed” metal chelators.
System and method for generating nonalcoholic fatty liver disease activity score (nas) using magnetic resonance ...
Mayo Foundation For Medical Education And Research
May 24, 2018 - N°20180140219

The present disclosure relates to a system and method for non-invasively determining nafld activity scores (nas) in patients using mechanical properties determined through magnetic resonance elastography (mre) imaging. The non-invasively determined nas score is then used to diagnose nfald and nash patients..
Analogues of vdac1-derlved peptides
The National Institute For Biotechnology In The Negev Ltd.
May 17, 2018 - N°20180134760

The present invention relates to peptides comprising analogues of vdac1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty ...
Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
University Of Kansas
May 17, 2018 - N°20180133274

Cosmetic and dietary supplement compositions containing silymarin and sulfoalkyl ether cyclodextrin, particularly sulfobutyl ether cyclodextrin, are described. The compositions and methods are useful in reducing appearance of facial redness in rosacea-prone skin, rejuvenating skin, preventing skin aging, inhibiting oxidative stress in epidermal and dermal cells, increasing collagen production, reducing the likelihood of skin cancer, treating or reducing liver damage from ...
Liver Disease Patent Pack
Download 100+ patent application PDFs
Liver Disease Patent Applications
Download 100+ Liver Disease-related PDFs
For professional research & prior art discovery
inventor
  • 100+ full patent PDF documents of Liver Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Benzothiazole or benzoxazole compounds as sumo activators
Icahn School Of Medicine At Mount Sinai
May 10, 2018 - N°20180127407

Provided are sumo activators, which can enhance sumoylation of serca2a, which are useful in the treatment of heart failure, cardiovascular diseases, cancer, neurodegenerative disorders, viral infection, bacterial infection, liver disease, inflammation, and other diseases.. .
Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination ...
Volant Holdings Gmbh
May 10, 2018 - N°20180125870

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the ...
Treatment for hepatic fibrosis
Galmed Research And Development Ltd.
May 10, 2018 - N°20180125862

The invention relates to the treatment and reduction of fibrosis, specifically hepatic fibrosis. More specifically, embodiments of the invention provide compositions and methods useful for the treatment and inhibition of hepato-fibrotic conditions associated with non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), employing the use of 3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid (...
Clinical gene signature-based human cell culture model and uses thereof
Icahn School Of Medicine At Mount Sinai
May 03, 2018 - N°20180119096

The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis c infection, persistent hepatitis b infection or ethanol exposure induces a clinical prognostic liver signature (pls) high-risk gene signature. The cellular model system for hepatocellular carcinoma (hcc)/cirrhosis development and progression may be used in the screening of compounds useful in the treatment and/...
Methods of treating liver disease using indane acetic acid derivatives
T3d Therapeutics, Inc.
May 03, 2018 - N°20180117013

This invention describes the use of indane acetic acid derivatives which are dual ppar delta/gamma agonists for the treatment of liver diseases including one or more of the following: nafld (non alcoholic fatty liver disease), nash (non alcoholic steatohepatitis), farber's disease, aclf (acute-on-chronic liver failure), clf (chronic liver failure), polt-hcv-svr (post-orthotopic liver transplant due to hepatitis c virus infection ...
Methods and compositions for preventing or treating fatty liver, protecting liver function or ameliorating liver ...
Sinew Pharma Inc.
May 03, 2018 - N°20180117003

The present invention relates to methods and compositions for preventing or treating fatty liver, protecting liver function or ameliorating liver diseases caused by fatty liver or other associated disorders.. .
Modulators of farnesoid x receptor and methods for the use thereof
Xiamen University
May 03, 2018 - N°20180116993

Compounds, compositions and methods are provided for treating the fxr-mediated disease or process in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound claimed, wherein the fxr-mediated disease or condition linked to chronic liver diseases such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis; gastrointestinal diseases; cardiovascular diseases; metabolic diseases such as diabetes and obesity; ...
Method for measuring glycoprotein, method for examining liver disease, reagent for quantitative determination of glycoprotein, ...
National Center For Global Health And Medicine
April 19, 2018 - N°20180106814

An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is ...
Loading